07:05 AM EST, 11/22/2024 (MT Newswires) -- GSK (GSK) said Friday that Japan's Ministry of Health, Labour and Welfare has approved an extension of the indication of Arexvy for the prevention of respiratory syncytial virus disease to include adults aged 50 to 59 at increased risk.

Since Sept. 2023, GSK's RSV vaccine has been approved in Japan for adults aged 60 and over.

RSV is a common virus affecting the respiratory system and can, in vulnerable populations, lead to pneumonia, hospitalization, or death.